Genetic risk scores enhance the diagnostic value of plasma biomarkers of brain amyloidosis
Vijay K. Ramanan(Mayo Clinic), Prashanthi Vemuri(Mayo Clinic in Arizona), Jonathan Graff‐Radford(Mayo Clinic in Arizona), Ekaterina I. Hofrenning(Mayo Clinic in Florida), Alicia Algeciras‐Schimnich(Mayo Clinic), Ronald C. Petersen(Mayo Clinic), Robel K Gebre(Mayo Clinic), David S. Knopman(Mayo Clinic), Owen A. Ross(Jacksonville College), Daniel J. Figdore(Mayo Clinic), Val J. Lowe(Mayo Clinic in Arizona), Michelle M. Mielke(Mayo Clinic), Clifford R. Jack(Mayo Clinic)
Cited by 24
Related Papers
Mild cognitive impairment as a diagnostic entity
|Journal of Internal Medicine|2004|7.8k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review) [RETIRED]
|Neurology|2001|2.1k
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
|Alzheimer s & Dementia|2024|2.1k
Primary age-related tauopathy (PART): a common pathology associated with human aging
|Acta Neuropathologica|2014|1.5k